Abstract
Celgene has agreed to acquire Avila Therapeutics in a deal that is valued at up to US$925 M. With the acquisition, Celgene will gain AVL-292, an oral Bruton’s tyrosine kinase (Btk) inhibitor in Phase I development for haematological malignancies and autoimmune diseases, and Avila’s Avilomics™ platform for the discovery and development of targeted covalent drugs. The deal, which has been approved by the Boards of Directors of both companies, is expected to complete during the first quarter of 2012.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
